131 related articles for article (PubMed ID: 37985961)
21. Predictive Factors of Central-Compartment Lymph Node Metastasis for Clinical N0 Papillary Thyroid Carcinoma With Strap Muscle Invasion.
Xue S; Zhang L; Pang R; Wang P; Jin M; Guo L; Zhou Y; Dong B; Chen G
Front Endocrinol (Lausanne); 2020; 11():511. PubMed ID: 33013682
[No Abstract] [Full Text] [Related]
22. Risk Factors for Central Compartment Lymph Node Metastasis in Papillary Thyroid Microcarcinoma: A Meta-Analysis.
Qu N; Zhang L; Ji QH; Chen JY; Zhu YX; Cao YM; Shen Q
World J Surg; 2015 Oct; 39(10):2459-70. PubMed ID: 26099728
[TBL] [Abstract][Full Text] [Related]
23. BRAF V600E mutation independently predicts central compartment lymph node metastasis in patients with papillary thyroid cancer.
Howell GM; Nikiforova MN; Carty SE; Armstrong MJ; Hodak SP; Stang MT; McCoy KL; Nikiforov YE; Yip L
Ann Surg Oncol; 2013 Jan; 20(1):47-52. PubMed ID: 22941165
[TBL] [Abstract][Full Text] [Related]
24. Role of BRAF V600E mutation as an indicator of the extent of thyroidectomy and lymph node dissection in conventional papillary thyroid carcinoma.
Kim SK; Woo JW; Lee JH; Park I; Choe JH; Kim JH; Kim JS
Surgery; 2015 Dec; 158(6):1500-11. PubMed ID: 26120069
[TBL] [Abstract][Full Text] [Related]
25. A meta-analysis evaluating the relationship between B-type Raf kinase mutation and cervical lymphatic metastasis in papillary thyroid cancer.
Ma H; Wang R; Fang J; Zhong Q; Chen X; Hou L; Feng L; Chen X; Huang Z; Zhao H
Medicine (Baltimore); 2020 Jan; 99(5):e18917. PubMed ID: 32000400
[TBL] [Abstract][Full Text] [Related]
26. Management of cN0 papillary thyroid microcarcinoma patients according to risk-scoring model for central lymph node metastasis and predictors of recurrence.
Feng JW; Ye J; Wu WX; Qu Z; Qin AC; Jiang Y
J Endocrinol Invest; 2020 Dec; 43(12):1807-1817. PubMed ID: 32557354
[TBL] [Abstract][Full Text] [Related]
27. Risk and Prognostic Factors for BRAF
Wei X; Wang X; Xiong J; Li C; Liao Y; Zhu Y; Mao J
Biomed Res Int; 2022; 2022():9959649. PubMed ID: 35647194
[TBL] [Abstract][Full Text] [Related]
28. Correlation between US-FNAC with BRAF V600E Mutation Analysis and Central Neck Lymph Node Metastasis in cN0 Papillary Thyroid Cancer.
Li R; Hao J; Zhu Z; Qiao X; Wang L; Zhou Z
Biomed Res Int; 2021; 2021():9937742. PubMed ID: 34307677
[TBL] [Abstract][Full Text] [Related]
29. Clinical risk factors for central lymph node metastasis in papillary thyroid carcinoma: a systematic review and meta-analysis.
Qu H; Sun GR; Liu Y; He QS
Clin Endocrinol (Oxf); 2015 Jul; 83(1):124-32. PubMed ID: 25130203
[TBL] [Abstract][Full Text] [Related]
30. Effects of Patient and Tumor Characteristics on Central Lymph Node Metastasis in Papillary Thyroid Cancer: A Guide for Selective Node Dissection.
Altiner S; Kozan R; Emral AC; Taneri F; Karamercan A
Arch Iran Med; 2022 Nov; 25(11):730-736. PubMed ID: 37543897
[TBL] [Abstract][Full Text] [Related]
31. Analysis of Risk Factors Associated With Central Lymph Node Metastasis in Papillary Thyroid Carcinoma With cT1N0 Stage.
Zhao YZ; He NA; Ye XJ; Jin F; Li MX; Jiang X
Front Endocrinol (Lausanne); 2022; 13():880911. PubMed ID: 35733781
[TBL] [Abstract][Full Text] [Related]
32. Ultrasonic Characteristics Improve Prediction of Central Lymph Node Metastasis in cN0 Unifocal Papillary Thyroid Cancer.
Liu Y; Huang J; Zhang Z; Huang Y; Du J; Wang S; Wu Z
Front Endocrinol (Lausanne); 2022; 13():870813. PubMed ID: 35795144
[TBL] [Abstract][Full Text] [Related]
33. Prediction of occult central lymph node metastasis in papillary thyroid carcinoma by preoperative BRAF analysis using fine-needle aspiration biopsy: a prospective study.
Joo JY; Park JY; Yoon YH; Choi B; Kim JM; Jo YS; Shong M; Koo BS
J Clin Endocrinol Metab; 2012 Nov; 97(11):3996-4003. PubMed ID: 22930785
[TBL] [Abstract][Full Text] [Related]
34. BRAF V600E mutation: Differential impact on central lymph node metastasis by tumor size in papillary thyroid carcinoma.
Kim SK; Lee JH; Woo JW; Park I; Choe JH; Kim JH; Kim JS
Head Neck; 2016 Apr; 38 Suppl 1():E1203-9. PubMed ID: 26268700
[TBL] [Abstract][Full Text] [Related]
35. The predictive value of coexisting BRAFV600E and TERT promoter mutations on poor outcomes and high tumour aggressiveness in papillary thyroid carcinoma: A systematic review and meta-analysis.
Chen B; Shi Y; Xu Y; Zhang J
Clin Endocrinol (Oxf); 2021 May; 94(5):731-742. PubMed ID: 32816325
[TBL] [Abstract][Full Text] [Related]
36. Conventional Ultrasound, Immunohistochemical Factors and BRAF
Chen J; Li XL; Zhao CK; Wang D; Wang Q; Li MX; Wei Q; Ji G; Xu HX
Ultrasound Med Biol; 2018 Nov; 44(11):2296-2306. PubMed ID: 30100099
[TBL] [Abstract][Full Text] [Related]
37. Development of a nomogram for prediction of central lymph node metastasis of papillary thyroid microcarcinoma.
Qiu P; Guo Q; Pan K; Lin J
BMC Cancer; 2024 Feb; 24(1):235. PubMed ID: 38378515
[TBL] [Abstract][Full Text] [Related]
38. Prophylactic central lymph node dissection performed selectively with cN0 papillary thyroid carcinoma according to a risk-scoring model.
Zhong X; Lu Y; Yin X; Wang Q; Wang F; He Z
Gland Surg; 2022 Feb; 11(2):378-388. PubMed ID: 35284301
[TBL] [Abstract][Full Text] [Related]
39. Prophylactic central lymph node dissection in cN0 patients with papillary thyroid carcinoma: A retrospective study in China.
Xue S; Wang P; Liu J; Li R; Zhang L; Chen G
Asian J Surg; 2016 Jul; 39(3):131-6. PubMed ID: 26117203
[TBL] [Abstract][Full Text] [Related]
40. Relevance and clinicopathologic relationship of BRAF V600E, TERT and NRAS mutations for papillary thyroid carcinoma patients in Northwest China.
Huang M; Yan C; Xiao J; Wang T; Ling R
Diagn Pathol; 2019 Jul; 14(1):74. PubMed ID: 31300059
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
